Intelligo

Private limited company · Oslo

GENTILI PHARMA AS

ActiveManufacture of pharmaceutical preparations (21.200)

Founded
1 May 2023
Business address
Dronningens gate 3, 0152 Oslo

The life line 2023–2026

Operating revenue per year, with recorded events above. As a table

Operating revenue 2025: NOK 122.3m.

  1. Chair took office§ 07
  2. Founded§ 16

Sources: the Register of Company Accounts (company accounts), fetched 1 Nov 2026; the Brønnøysund Register Centre. Each event has the colour of the section it is in.

In brief

GENTILI PHARMA AS is a private limited company in Oslo, founded in 2023, in the industry manufacture of pharmaceutical preparations. The chair of the board is Angelo Pelliccioni. In 2025 the company had NOK 122.3m in operating revenue and a net profit of NOK 59.2m.

Put together by Intelligo from the sections below; each figure stands with its source where it belongs.

Overview

§ 01 Latest changes

4 changes, latest 8 Sep 2026

  • Won a tender from Pohjois-Pohjanmaan hyvinvointialue
  • Annual accounts filed 2024 → 2025
  • Lost a tender: Läkemedel 2025 del 2
  • Endring av styre

Source: the Brønnøysund Register Centre and Intelligo's own observations, fetched 15 Nov 2026 · All events →

Overview

§ 02 Worth knowing

1 point

  • OKEquity ratio 70.7%, above the industry median

Assumed: derived by Intelligo by fixed rules, not a credit rating. How we calculate

Overview

§ 03 Key figures

Revenue NOK 122.3m in 2025

Revenue

NOK 122.3m

— from 2024

20232025

Operating profit

NOK 75.9m

+1,362,020.5% from 2024

20232025

Net profit

NOK 59.2m

+1,390,823.5% from 2024

20232025

Equity

NOK 59.3m

+106,279.0% from 2024

20232025

Demerger carried out 29 Jan 2024: the figures before and after are not the same business.

Source: the Register of Company Accounts, read 1 Nov 2026 · The full accounts →

Finances

§ 04 Where the money comes from and goes

Financial year 2025

Of every krone of operating revenue in 2025:

  • Wages and social costs 6%
  • Depreciation 1%
  • Other operating costs 12%
  • Not specified in the source 21%
  • Left as operating result 60%

Source: the Register of Company Accounts via areg.no, read 15 Nov 2026

Finances

§ 05 Financial health

Equity ratio 70.7%

RevenueNOK 122.3m Operating margin62.0% Equity ratio70.7%
  • GENTILI PHARMA AS, 2025
  • Industry median, assumed: NOK 31.9m · 7.0% · 50.3%

Equity NOK 59.3m71% of the assets (NOK 83.9m)

Source: the Register of Company Accounts, read 1 Nov 2026. The median is derived by Intelligo from 28 companies in 21.200 Manufacture of pharmaceutical preparations, not stated by the source.

Finances

§ 06 Accounts

2 years, latest 2025

NOK 1,0002024–2520252024
Operating revenue122,346—
Operating profit75,859−6
Profit before tax75,754−5
Net profit59,203−4
Total assets83,87356
Equity59,29956
Liabilities24,5750

Source: the Register of Company Accounts, read 1 Nov 2026 · All 2 years →

Management and ownership

§ 07 Officers

3 officers now

The board: 1 member

Source: the Brønnøysund Register Centre, read 23 Oct 2026 · All 3 roles, former ones too →

Management and ownership

§ 08 Signature, procuration and authorisations

Styrets leder alene.

May sign for the company:

Styrets leder alene.

Procuration: none registered.

The signature is word for word from the register. Source: the Register of Business Enterprises, read 5 Oct 2026

Management and ownership

§ 09 Owners

None registered

No owners registered.The Tax Administration's shareholder register covers limited companies and has no owners for this business. Checked 15 Nov 2026.

Management and ownership

§ 10 Group

None registered

Not a group.No subsidiaries in the shareholder register, and no group accounts. Checked 15 Nov 2026.

Management and ownership

§ 11 Portfolio

None registered

No holdings registered.The shareholder register has no shares held by the company. Checked 15 Nov 2026.

Management and ownership

§ 12 Network

None registered

No connections.Nobody with a role here has roles in other companies. Checked 15 Nov 2026.

Events and registers

§ 13 Events

25 since 2023

Events per year

20232026

  • Notices23
  • Register changes1
  • Tenders won1

Since 2023: 23 announcements, 1 register change and 1 tender won. Most happened in 2023 and 2024.

Source: the announcements of the Brønnøysund Register Centre, the Tax Administration's Register of Shareholders, Doffin, TED and NAV, read 16 Nov 2026. Register changes are Intelligo's own observations. · All 25 events →

Events and registers

§ 14 Notices

23, latest 13 Nov 2025

  • Styre
  • Kapital
  • Vedtektsdato

Source: The Brønnøysund Register Centre's announcements ↗, read 16 Nov 2026 · All 23 →

Events and registers

§ 15 Charges

Not fetched yet

Events and registers

§ 16 Other registers

Found in 3 of 7

  • The Central Coordinating RegisterRegistered 1 Jun 2023
  • VATRegistered
  • The Register of Business EnterprisesRegistered 1 Jun 2023
  • The Cleaning RegisterNot registered
  • The Register of Staffing AgenciesNot registered
  • Smiley scheme, the Norwegian Food Safety AuthorityNot registered
  • The Financial Supervisory Authority's licence registerNot registered

Purpose: a. å produsere og handle med kjemiske og biologiske produkter for den farmasøytiske industrien, herunder innenfor medisinske spesialiteter, galeniske, dietetiske, ernæringsmessige og fytoterapeutiske produkter. b. å stifte, delta i, på hvilken som helst måte, samt administrere og føre tilsyn med, virksomheter og selskaper. c. å finansierevirksomheter og selskaper. d. å låne, låne ut og tilveiebringe midler, herunder ved utstedelse av obligasjoner, gjeldsbrev eller andre verdipapirer eller bevis på gjeld, samt å inngå avtaler i forbindelse med nevnte aktiviteter e. å yte råd og tjenester til virksomheter og selskaper som inngår i samme konsern som selskapet, samt til tredjeparter f. å gi garantier, forplikte selskapet, samt å pantsette selskapets eiendeler som sikkerhet for forpliktelser tilhørende andre virksomheter og selskaper som inngår i samme konsern som selskapet, samt på vegne av tredjeparter g. å erverve, avhende, administrer og utnytte fast eiendom, og andre eiendeler generelt h. å handle med valuta, verdipapirer og eiendeler generelt i. å utvikle og handle med patenter, varemerker, lisenser knowhow og andre immaterielle rettigheter j. å utføre alle aktiviteter av industriell, finansiell eller kommersiell art samt alt som står i naturlig forbindelse med det forannevnte, i sin videste forstand.

Source: the Brønnøysund Register Centre, the Labour Inspection Authority, the Food Safety Authority and the Financial Supervisory Authority, each on its own, fetched 15 Nov 2026

Market

§ 17 Tenders

2 tenders

  • 2025
  • 2026
  • Won
  • Lost
AwardedContractBuyerOutcome
Sep 2026Lääkevalmisteet ja niihin rinnastettavat tuotteet hankintakaudelle 1.1.2026-31.12.2027Pohjois-Pohjanmaan hyvinvointialueWon
Dec 2025Läkemedel 2025 del 2Region Skåne, Koncernstab inköp och ekonomistyrningLost

Source: Doffin and TED, read 8 Sep 2026. · All 2 tenders →

Market

§ 18 Vacancies

None registered

No vacancies.No open ads at NAV. Checked 15 Nov 2026.

Market

§ 19 Competitors

Industry code 21.200

The companies most like it:

Compare them

The selection is Intelligo's, not stated by the source: companies met in tenders and winners of tenders of the same kind, otherwise the same industry code, nearest in place and size. Source: the Brønnøysund Register Centre, Doffin and TED, fetched 15 Nov 2026 · All competitors → · Largest in the industry →

Last

§ 20 Questions and answers

5 questions

  • What was the revenue in 2025?
    NOK 122.3m in the company. § 06
  • Who can sign for GENTILI PHARMA AS?
    Styrets leder alene. § 08
  • Who is the auditor?
    KPMG AS, from 30 Oct 2023. § 07
  • Where is GENTILI PHARMA AS based?
    Dronningens gate 3, 0152 Oslo.
  • When was GENTILI PHARMA AS founded?
    1 May 2023, registered in the Register of Business Enterprises 1 Jun 2023. § 16

The answers come from the sections linked to, with their sources.

01Latest changesOverviewContentsClose